EP1418947A1 - Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes - Google Patents

Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes

Info

Publication number
EP1418947A1
EP1418947A1 EP02762786A EP02762786A EP1418947A1 EP 1418947 A1 EP1418947 A1 EP 1418947A1 EP 02762786 A EP02762786 A EP 02762786A EP 02762786 A EP02762786 A EP 02762786A EP 1418947 A1 EP1418947 A1 EP 1418947A1
Authority
EP
European Patent Office
Prior art keywords
glycyl
pharmaceutical composition
glycine
polysaccharide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02762786A
Other languages
German (de)
English (en)
Inventor
Takayuki Kawaguchi
Satoshi Okuno
Toshiro Yano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of EP1418947A1 publication Critical patent/EP1418947A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the present invention relates to a pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor. More particularly, the present invention relates to a pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity, for example, a camptothecin derivative of the formula (I) or (II) as mentioned below, via an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different, or a salt thereof.
  • a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity, for example, a camptothecin derivative of the formula (I) or (II) as mentioned below, via an amino acid or a peptide consisting of 2 to 8
  • Malignant tumors are one of the main causes of death in the developed countries, and the majority of malignant tumors related deaths are due to metastasis into distant organs or recurrence accompanied by metastasis to distant organs after a topical therapy.
  • the metastasis to distant organs may be caused by hematogenous metastasis or lymphogenous metastasis, and it is known that a patient having lymphogenous metastasis has a high risk of recurrence of a malignant tumor after topical therapy.
  • the main organs of recurrence are brain, lung, liver, and bone.
  • a tumor in digestive apparatus for example, colon cancer from which a large number of patients are suffered, may often invade and spread to the liver, and a breast cancer and a lung cancer as well often invade and spread to the liver.
  • a lymphoma and a lymphatic leukemia may spread mainly to the lymph system, and it has been reported that the metastasis to liver was observed in high rate by autopsy.
  • a chemotherapy, etc. is employed as a supportive care after a topical therapy, but the chemotherapy has a potent toxicity and cannot be used for chronic administration.
  • WO 94/19376, WO 97/46260, WO 97/38727, JP-A-10-72467 and JP-A-10-95802 disclose a polysaccharide derivative comprising a polysaccharide bound to an active substance having an anti-tumor activity via an amino acid or a peptide.
  • An object of the present invention is to provide a novel pharmaceutical composition for inhibiting the metastasis or preventing the recurrences of a malignant tumor.
  • the present inventors have intensively studied, and have found that a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide exhibits an excellent effect in the inhibition of metastasis and/or prevention of recurrence of a malignant tumor, and have accomplished the present invention.
  • the present invention relates to pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different, or a salt thereof.
  • Fig 1 shows the lapsed days after implantation of tumor and the number of survived animals in M 5076 liver metastatic models.
  • the polysaccharide having a carboxyl group of the present invention includes the same ones as those disclosed in the above mentioned WO 94/19376 and WO 97/46260, and includes polysaccharide having originally carboxyl groups in the structure thereof (e.g., hyaluronic acid, pectic acid, alginic acid, chondroitin, heparin, etc.), and polysaccharides having originally no carboxyl group (e.g., pullulan, dextran, mannan, chitin, mannoglucan, chitosan, etc.) but being introduced thereto carboxyl groups, and polysaccharides having originally no carboxyl group in the structure thereof but being introduced thereto carboxyl groups after polyalcohol formation (e.g., polysaccharide polyalcohol having a carboxyl group) .
  • the polysaccharide having originally no carboxyl group but being introduced thereto a carboxyl group means ones that are prepared by substituting a hydrogen atom of a part or all of hydroxyl groups of polysaccharides having originally no carboxyl group with a carboxy-C ⁇ alkyl group.
  • the polysaccharide having a polysaccharide includes one that are prepared by treating a polysaccharide originally having no carboxyl group with a reducing agent, and then followed by substituting a hydrogen atom of a part or all of hydroxyl groups of the resultant with a carboxy-C ⁇ alkyl group.
  • the polysaccharide polyalcohol having a carboxyl group includes, for example, a carboxy-C ⁇ alkyl-polysaccharide polyalcohol which is prepared by treating a polysaccharide originally having no carboxyl group successively with sodium periodate and sodium borohydride by the method disclosed, in WO 97/46260 to give a polysaccharide polyalcohol, which is further treated with a halogenated Ci. 4 alkylcarboxylic acid.
  • the alkyl moiety of the carboxyl-Ci., alkyl group which substitutes a hydrogen atom of the hydroxyl groups of the above polysaccharide may be either a straight chain alkyl group or a branched chain alkyl group.
  • alkyl group is, for example, carboxymethyl group, 1-carboxyethyl group, 3-carboxypropyl group, l-methyl-3-carboxypropyl group, 2-methyl-3-carboxy- propyl group, 4-carboxybutyl group, etc., and carboxymethyl group is more preferable.
  • the polysaccharide having a carboxyl group is preferably carboxy-C ⁇ alkyldextran or carboxy-Ci. 4 alkyldextran polyalcohol, and carboxyl-C ⁇ alkyldextran is especially preferable.
  • the degree of polyalcohol formation (by the successive oxidation with sodium periodate and reduction with sodium borohydride) in the step of preparing the carboxy-C 1 _ 4 alkyl-polysaccharide polyalcohol as mentioned above is not specified, but the intermediate polysaccharide polyalcohol is preferably one being obtained by treating a polysaccharide under possible conditions for substantially almost completely forming polyalcohol.
  • the polysaccharide having a carboxyl group is preferably carboxymethylated dextran or carboxymethylated dextran polyalcohol, and among these polysaccharides, particularly dextran having an average molecular weight of 20,000 to 500,000 is more preferable, and dextran having an average molecular weight of 50,000 to 350,000 is most preferable (said average molecular weight being determined by Gel permeation chromatography (GPC) method, Shinseikagaku, Jikken Koza, vol. 20, p. 7, Tokyo-Kagaku-Dojin, November 5, 1991).
  • GPC Gel permeation chromatography
  • degree of the introduction thereof is expressed by "degree of substitution" which is defined by a number of carboxylalkyl groups (including groups of peptide chain being introduced by these groups) per a sugar residue. That is expressed by the following equation.
  • the degree of substitution is occasionally expressed by the degree of carboxy ethylation (CM-degree) .
  • CM-degree degree of carboxy ethylation
  • the degree of substitution thereof is preferably in the range of 0.3 to 0.8.
  • the degree of substitution is preferably in the range of 0.3 to 0.5.
  • the amino acid or peptide of the present invention plays a role of spacer existing between a polysaccharide having a carboxyl group and an active substance having an anti-tumor activity, and the amino acid or amino acid forming said peptide includes both natural amino acids and synthetic amino acid (including D-amino acids, L-amino acids, a mixture thereof) , and also includes either neutral amino acids, basic amino acids or acidic amino acids.
  • the amino acid of the present invention may be not only ⁇ -amino acid but also ⁇ -amino acids, ⁇ -amino acids, ⁇ -amino acids, etc.
  • amino acids examples include glycine, ⁇ -alanine, ⁇ - alanine, valine, leucine, isoleucine, serine, threonine, systeine, methionine, aspartic acid, glutamic acid, lysine, citrulline, arginine, phenylalanine, tyrosine, histidine, tryptophan, proline, hydroxyproline, ⁇ -aminobutyric acid, ⁇ -aminocaproic acid, etc.
  • the peptide of the present invention includes ones consisting of 2 to 8 amino acids, preferably 2 to 5 amino acids, which are the same or different.
  • Examples of the peptides are glycyl-glycyl-L- or D-phenylalanyl-glycine, glycyl-glycine, glycyl-glycyl-glycine, glycyl-glycyl-glycine, glycyl-glycyl-glycyl-glycine, L- or D-phenylalanyl-glycine, L- or D-tyrosyl-glycine, L- or D- leucyl-glycine, L- or D-phenylalanyl-citrulline and L- or D-valyl-citrullin (the N-terminus of these peptides is introduced onto the carboxyl group of a polysacc
  • glycyl-glycyl-L- or D-phenylalanyl-glycine glycyl-glycine, glycyl-glycyl-glycine, glycyl-glycyl-glycine, glycyl-glycyl-glycyl-glycine, and L- or D-phenylalanyl-glycine are preferable.
  • the active substance having an anti-tumor activity of the present invention may include various compounds being known as an anti-tumor agent, and may be either cytotoxic agents or cytostatic agents.
  • the cytotoxic agent is preferably camptothecin derivatives and taxane derivatives, and the cytostatic agent is preferably angiogenesis inhibitors, EGF receptor inhibitors. More preferably, the cytotoxic agent is camptothecin derivatives, and the cytostatic agent is angiogenesis inhibitors.
  • camptothecin derivatives are compounds disclosed in JP-A-10-72467 of the formula (I) : wherein R 1 is a substituted or unsubstituted lower alkyl group, X 1 is a group of the formula: -NHR 2 (R 2 is a hydrogen atom or a lower alkyl group) and Alk is a straight chain or branched chain C ⁇ alkylene group having optionally an oxygen atom in the chain thereof.
  • preferable compound is 10- (3' -aminopropyloxy) -7-ethyl- (20S) - camptothecin.
  • camptothecin derivatives are compounds disclosed in JP-A-10-95802 of the formula (II) :
  • R 2 to R 6 being adjacent each other combine to form a lower alkylene group, and one of the carbon atoms of said lower alkylene group is substituted by an amino group, and the remaining three groups of R 2 to R 6 are a hydrogen atom, a lower alkyl group or a halogen atom.
  • preferable compound is (IS, 9S) -l-amino-9- ethyl-5-fluoro-2, 3-dihydro-9-hydroxy-4-methyl-lH, 12H- benzo [de]pyrano [3' , 4' : 6, 7] indolidino [1, 2-b] quinoline- 10,13(9H,15H)-dione, etc.
  • taxane derivatives are Taxol, Taxotere, 13- [ (2 ' R, 3 ' R) -3 'N-t-butyloxycarbonyl-3 ' -cyclopropyl] -10- deacetyl-baccatin III, etc.
  • the ratio of the polysaccharide and the active substance having an anti-tumor activity may be selected according to the kinds of the polysaccharide to be used, but when the polysaccharide is dextran or dextran polyalcohol, then the content of the active substance having an anti-tumor activity is preferable in the range of 0.1 to 20 % by weight, more preferably in the range of 2 to 10 % by weight, based on the whole weight of the active ingredient.
  • preferable ones are polysaccharide derivatives or a salt thereof wherein an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different are introduced into a part or all of the carboxyl groups of the polysaccharide having a carboxyl group through an acid- amide bond, and the remaining part or all of the amino groups or carboxyl groups which do not participate in the binding to the carboxyl groups of the above peptide are bound to the carboxyl groups, amino groups or hydroxyl groups of the active substance having an anti-tumor activity through an acid-amide bond or ester bond.
  • Especially preferable active ingredient is a polysaccharide derivative, wherein the polysaccharide having an carboxyl group is carboxymethylated dextran, the active substance having an anti-tumor activity is 10- (3'- aminopropyloxy) -7-ethyl- (20S) -camptothecin, and the peptide is glycyl-glycyl-glycine, or a salt thereof.
  • the polysaccharide derivative wherein the polysaccharide having a carboxyl group is carboxymethylated dextran having an average molecular weight of 60,000 to 200,000, and the degree of carboxymethylation thereof is in the range of 0.3 to 0.8, or a salt thereof.
  • Other preferable active ingredient is a polysaccharide derivative wherein the polysaccharide having a carboxyl group is a carboxy-C ⁇ alkyldextran polyalcohol, the active substance having an anti-tumor activity is (IS, 9S)-1- amino-9-ethyl-5-fluoro-2, 3-dihydro-9-hydroxy-4-methyl- 1H, 12H-benzo [de]pyrano [3' , 4' : 6, 7] indolidino [1, 2-b] - quinoline-10, 13 (9H, 15H) -dione, and the peptide is glycyl- glycyl-L- or D-phenylalanyl-glycine, or a salt thereof, and especially preferable ones are a polysaccharide derivative or a salt thereof wherein the polysaccharide having a carboxyl group is carboxy-C !
  • alkyldextran polyalcohol having an average molecular weight of 200,000 to 400,000, and the degree of the substitution thereof is in the range of 0.3 to 0.5.
  • the polysaccharide derivative or a salt thereof of the. active ingredient of the present invention may be prepared according to the methods disclosed in WO 94/19376, WO 97/46260, WO 97/38727, JP-A-10-72467, and JP-A-10-95802.
  • the pharmaceutical composition of the present invention may highly accumulate at the site such as lymph node or the liver to which cancers may spread, can release an active substance at an appropriate rate so that the active substance hardly affects on the normal cells and suppressively acts on the growth of tumor cells, and hence, the pharmaceutical composition of the present invention is useful in the inhibition of metastasis or prevention of reoccurrence of a malignant tumor.
  • the pharmaceutical composition of the present invention is useful in the inhibition of lymph node metastasis or liver metastasis, particularly useful in the inhibition of lymph node metastasis.
  • the present pharmaceutical composition is useful in the inhibition of metastasis in lymph node from the colon, or metastasis in lymph node from the lung.
  • the present pharmaceutical composition may exhibit its effects not only before the onset of metastasis but also after the onset of metastasis. Therefore, the present pharmaceutical composition is also useful in the inhibition of metastasis or prevention of reoccurrence of a malignant tumor after a topical therapy (e.g., surgery, radiation therapy, thermotherapy, cryotherapy, laser burning therapy, etc.). Moreover, the present pharmaceutical composition is also suitable for repetitive dosing for long time, and can be employed together with a topical therapy.
  • a topical therapy e.g., surgery, radiation therapy, thermotherapy, cryotherapy, laser burning therapy, etc.
  • the present pharmaceutical composition is preferably administered parenterally (e.g., intravenous injection), and is usually administered in the form of a liquid preparation such as solution, suspension, emulsion, etc.
  • the present pharmaceutical composition is preferably formulated in the form of an injection or drip infusion by using distilled water for injection, physiological saline solution, aqueous glucose solution.
  • the dosage of the present pharmaceutical composition may vary according to the administration methods, age, weight or conditions of the patients, etc., but it is usually in the range of 0.002 to 50 mg/kg, more preferably in the range of 0.01 to 5 mg/kg, in single dose, converted into an amount of the active substance.
  • the lower alkyl group and the lower alkylene group may be ones having 1 to 6 carbon atoms, preferably ones having 1 to 4 carbon atoms, and the halogen atom is fluorine atom, chlorine atom, bromine atom, iodine atom, etc.
  • mice One million of M 5076 cells (mouse ovarian sarcoma cells) were implanted into BDF1 male mice (5-weeks old, 8 animals per group) at the tail vein.
  • a test compound (Compound A; the compound obtained in Preparation 1 as described below and Irinotecan (CPT-11) ) was dissolved in a physiological saline solution, and each amount as indicated in Table 1 as mentioned below was administered intravenously to the mice on the 4th, 8th and 12th day after the implantation, and the mice were observed for 120 days after the implantation of tumor.
  • the control group untreated with test compound
  • only a physiological saline solution was administered.
  • the survival time (days) was measured in both the test compound-treated groups and the control group, and the prolongation rate of survival was calculated according to the following equation. The results are shown in Table 1 and Fig. 1.
  • Irinotecan (40 mg/kg) 10 7 0.58 0 1.0 1 0.58 1 1.0 7 0.58
  • MI Metastatic Incidence ** .
  • P means standard derivation, where all treated groups compared to Control by Fischer exact test.
  • HT-29 cells human colon cancer
  • a test compound (Compound A; the compound obtained in Preparation 1 as mentioned below, and Irinotechan (CPT-11)) was dissolved in a physiological saline solution, and each amount as indicated in Table 3 as mentioned below was administered intravenously to the mice on the 51st, 55th, 59th, and 63rd day after the implantation of tumor.
  • MI Metastatic Incidence ** .
  • P means standard derivation, where all treated groups compared to Control by Fischer exact test.
  • H460 cells human lung cancer
  • lOONCr nu/nu female mice 5 to 6 weeks old, 10 animals per group
  • a test compound (Compound A; the compound obtained in Preparation 1 as mentioned below, Compound B; the compound obtained in Preparation 4 as mentioned below, and Irinotechan (CPT-11) ) was dissolved in a physiological saline solution, and each amount as indicated in Table 4 as mentioned below was administered intravenously to the mice on the 14th, 18th, 22nd and 26th day after the implantation of tumor.
  • CM-Dextran means carboxymethyldextran, hereinafter, the same
  • the low molecule fractions were removed by using an ultrafiltration module (ACP-1010, manufactured by Asahi Kasei Industries, Ltd.), and the pH value thereof was adjusted to pH 8 with 0.1N aqueous sodium hydroxide solution, and then subjected to ion-exchange resin MSC-1 (Na-type, manufactured by Dowex) .
  • the fractions containing the desired compounds are concentrated, and filtered through a filter (0.45 ⁇ m) .
  • the resultant was mixed with ethanol (10 liters) with stirring, and thereto was added dropwise 3M brine (40 ml) under stirring.
  • the resulting precipitates were collected by filtration, and dissolved in purified water (21 liters) .
  • the pH value of the solution was adjusted to pH 4.0 with 0.2N aqueous hydrochloric acid solution, and subjected again to ultrafiltration during which the pH value was kept at pH 4.0.
  • the solvent was concentrated to the total volume of 1.5 liter, and filtered through a filter (0.45 ⁇ m) .
  • the resultant was mixed with ethanol (9 liters) , and thereto was added dropwise 3M brine (35 ml) under stirring.
  • the resulting precipitates were collected by filtration, and washed successively with ethanol and acetone, concentrated under reduced pressure to give the desired compound (54.9 g) as pale yellow powder.
  • the content as 10- (3* -aminopropyloxy) -7-ethyl- (20S) - camptothecin hydrochloride was confirmed as 4.2 % by absorption at 367.5 nm.
  • GPC Gel Permeation Chromatograph
  • CM-Dextran(2008 mg, CM-degree: 0.47, the average molecular weight: 170 kDa) was dissolved with stirring in purified water (90 ml), and thereto were added 13- [ (2 ' R, 3 ' S) -3 ' -N-tert-butoxycarbonyl-3 ' -phenyl-2 ' -O-L- phenylalanyl-glycyl-isoserinyl] -10-deacyl-baccatin III mesylate (119 mg) and dimethylformamide (90 ml), and the mixture was stirred so as to dissolve.
  • CM-Dextran (1.294g, CM-degree: 0.47, the average molecular weight: 170 kDa) was dissolved with stirring in purified water (70 ml), and thereto were added 2'-0-phenyl- alanyl-glycyltaxol mesylate (77 mg) and dimethylformamide (70 ml) , and the mixture was further stirred so as to dissolve.
  • 2-Ethoxy-l (2H) -quinolmecarboxylic acid (2.59 g) was added to the mixture under stirring, and the mixture was reacted with stirring overnight.
  • the reaction solution was added to ethanol (700 ml) under stirring, and thereto was added dropwise 3M brine (1.4 ml) under stirring.
  • Acetic buffer (0.1 M, pH 5.5, 1000 ml) was put into a three-neck round bottom flask (capacity; 3 liters) .
  • Dextran T-500® (10.0 g, manufactured by Amersham Pharmacia Biotech AB) was added in small portions to the buffer over a period of 30 minutes at room temperature. The mixture was stirred for about 30 minutes until the solution became clear, and then, the mixture was cooled at 5°C (inner temperature) in a bath.
  • the pH value of the reaction mixture was adjusted to below pH 5.5 by adding acetic acid thereto at 3 to 6°C, and the mixture was further stirred for 2 hours.
  • the pH value of the reaction mixture was adjusted to about pH 7.8 with 8M aqueous sodium hydroxide solution. The mixture was subjected to dialysis against water
  • CM- PA-Dextran carboxymethyldextran polyalcohol
  • the mixture was stirred for about 10 to 30 minutes until the mixture became clear, and then sodium hydroxide (pellet, 97.0 %, 21.8 g) was added to the dextran polyalcohol solution in small portions under stirring, during which the inner temperature was kept at 30 to 40°C in an ice bath.
  • the reaction flask was put in a bath, and the mixture was stirred at 30°C.
  • Chloroacetic acid (31.1 g) was added with stirring in small portions into the reaction mixture at 30 to 40°C. After the addition, the mixture was further stirred at 30°C in a bath for 20 hours.
  • the reaction mixture was cooled in an ice bath, and the mixture was neutralized by adding thereto acetic acid under stirring (i.e., the pH value was adjusted to below pH 9) .
  • the main fraction was subjected to dialysis (Spectora®/Por 3 membrane, Molecule weight cutoff ⁇ 3500), and lyophilized to give a crude product, which was pulverized with acetone, collected by filtration, and dried to give the desired product (904 mg) as pale yellow powder.
  • the pharmaceutical composition of the present invention may highly accumulate at the site such as lymph node or the liver to which cancers may spread, and suppressively act on the growth of tumor cells without affecting on the normal cells, and hence, the pharmaceutical composition of the present invention is useful in the inhibition of metastasis, particularly in the inhibition of lymph node metastasis or liver metastasis, or prevention of reoccurrence of a malignant tumor.
  • the present pharmaceutical composition may exhibit its effects not only before the onset of metastasis but also after the onset of metastasis. Therefore, the present pharmaceutical composition is also useful in the inhibition of metastasis or prevention of reoccurrence of a malignant tumor after topical therapy (e.g., surgery, radiation therapy, thermotherapy, cryotherapy, laser burning therapy, etc.).
  • topical therapy e.g., surgery, radiation therapy, thermotherapy, cryotherapy, laser burning therapy, etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention concerne une composition pharmaceutique permettant d'inhiber les métastases ou de prévenir la récurrence d'une tumeur maligne. Cette composition comprend en tant que principe actif un dérivé de polysaccharide composé d'un polysaccharide comprenant un groupe carboxyle lié a un composant actif à activité antitumorale par l'intermédiaire d'un acide aminé ou d'un peptide comprenant de 2 à 8 acides aminés identiques ou différents, ou un sel de ce composé. Les principes actifs préférés sont des dérivés de camptothécine.
EP02762786A 2001-08-21 2002-08-16 Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes Withdrawn EP1418947A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001249717 2001-08-21
JP2001249717 2001-08-21
PCT/JP2002/008309 WO2003015826A1 (fr) 2001-08-21 2002-08-16 Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes

Publications (1)

Publication Number Publication Date
EP1418947A1 true EP1418947A1 (fr) 2004-05-19

Family

ID=19078678

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02762786A Withdrawn EP1418947A1 (fr) 2001-08-21 2002-08-16 Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes

Country Status (18)

Country Link
EP (1) EP1418947A1 (fr)
KR (1) KR20040027972A (fr)
CN (1) CN100372570C (fr)
AR (1) AR035137A1 (fr)
AU (1) AU2002328093B2 (fr)
BR (1) BR0212036A (fr)
CA (1) CA2457056C (fr)
HU (1) HUP0401351A3 (fr)
IL (1) IL160148A0 (fr)
MX (1) MXPA04001599A (fr)
NO (1) NO20041194L (fr)
NZ (1) NZ530947A (fr)
PL (1) PL368319A1 (fr)
RU (1) RU2275913C2 (fr)
TW (1) TWI313609B (fr)
UA (1) UA75450C2 (fr)
WO (1) WO2003015826A1 (fr)
ZA (1) ZA200400917B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
FR2914305B1 (fr) * 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
DK2313487T3 (en) 2008-07-16 2018-06-18 Childrens Medical Center ORGANIZING DEVICE WITH MICRO-CHANNELS AND METHODS OF APPLICATION
WO2012166903A1 (fr) 2011-06-02 2012-12-06 President And Fellows Of Harvard College Procédés et utilisations associés à des systèmes de culture tissulaire ex vivo
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
DK2907824T3 (en) 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
DK3466976T3 (da) 2014-01-31 2021-12-13 Daiichi Sankyo Co Ltd Anti-her2-antistof-lægemiddelkonjugat
EP3292146A1 (fr) 2015-05-04 2018-03-14 Pfizer Inc Conjugués polysaccharide-protéine de streptococcus du groupe b, procédé de production de conjugués, compositions immunogènes comprenant les conjugués et leurs utilisations
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
WO2018110515A1 (fr) 2016-12-12 2018-06-21 第一三共株式会社 Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle immunitaire
KR102537651B1 (ko) 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
CA3073924C (fr) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Procede ameliore de production d'un conjugue anticorps-medicament
BR112020003466B1 (pt) 2017-08-31 2023-12-12 Daiichi Sankyo Company, Limited Métodos de produção de composto, e, composto
JP2021524740A (ja) 2018-05-18 2021-09-16 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134348C (fr) * 1993-02-26 2007-01-02 Hideo Nogusa Derives polysaccharidiques et vecteurs de medicaments
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (fr) * 1995-12-28 2004-04-20 Kenji Tsujihara Derives de la camptothecine
EP0895784B1 (fr) * 1996-04-15 2005-11-23 Asahi Kasei Kabushiki Kaisha Composite de medicaments contenant des derives de taxane ou de steroides
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1058038C (zh) * 1996-12-31 2000-11-01 中国科学院感光化学研究所 低收缩性光固化涂层材料及其制法和用途
CN1250293C (zh) * 1998-05-22 2006-04-12 第一制药株式会社 药物复合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03015826A1 *

Also Published As

Publication number Publication date
CA2457056C (fr) 2008-07-22
BR0212036A (pt) 2004-08-17
ZA200400917B (en) 2004-08-25
CN1545423A (zh) 2004-11-10
NO20041194L (no) 2004-03-19
IL160148A0 (en) 2004-07-25
TWI313609B (en) 2009-08-21
KR20040027972A (ko) 2004-04-01
WO2003015826A1 (fr) 2003-02-27
HUP0401351A3 (en) 2011-02-28
RU2004108141A (ru) 2005-04-20
HUP0401351A2 (hu) 2004-12-28
CA2457056A1 (fr) 2003-02-27
RU2275913C2 (ru) 2006-05-10
AU2002328093B2 (en) 2005-05-05
UA75450C2 (en) 2006-04-17
PL368319A1 (en) 2005-03-21
CN100372570C (zh) 2008-03-05
MXPA04001599A (es) 2004-07-08
AR035137A1 (es) 2004-04-14
NZ530947A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
AU2002328093B2 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor
AU2002328093A1 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor
US6436912B1 (en) Drug complexes
US5892043A (en) Camptothecin derivatives
ES2198421T3 (es) Derivados de la camptotecina unidos a polimeros.
EP0955064B1 (fr) Procede de fabrication de complexes medicamenteux
JP4717016B2 (ja) Ｏ，ｏ’−アミドマロネートおよびｎ，ｏ−アミドマロネート白金錯体
MXPA97000222A (en) Derivatives of camptotec
US20120041167A1 (en) Poly(glutamic acid)-drug conjugate with an amino acid as a linker
US20060052288A1 (en) Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
JPH1095802A (ja) カンプトテシン誘導体
JPH1171280A (ja) 医薬組成物
JP2527885B2 (ja) ヘパリン誘導体
EP3071238B1 (fr) Conjugué comprenant de l'indole-3-carbinol à usage médical
JP2003137818A (ja) 悪性腫瘍の転移抑制または再発予防用組成物
JP3322203B2 (ja) 医薬組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1065958

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MITSUBISHI TANABE PHARMA CORPORATION

17Q First examination report despatched

Effective date: 20071121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100303

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1065958

Country of ref document: HK